Case Studies

A growing Mexican fintech unicorn partnered with Speyside to enhance its brand visibility and public presence. Facing a competitive market, the company needed to build strong recognition and position its leaders as industry authorities. Speyside implemented a communications strategy focused on thought leadership and media engagement. Within a year, they secured 30 top-tier media interviews and over 100 impactful publications, boosting brand awareness and earning the company recognition in prestigious rankings like Expansión’s 41+1 Leaders, LinkedIn’s Best 10 Startups to Work For, and Great Place to Work.

To support diabetes policy reform in Mexico, a pharmaceutical company worked with Speyside to go beyond glucose control and emphasize the prevention of cardiovascular and kidney complications. Speyside implemented a multi-phase strategy that included stakeholder mapping, policy analysis, communication campaigns, and workshops. The project engaged policy champions and strengthened collaboration between patient groups, health professionals, and policymakers—laying the groundwork for a national response that prioritizes early diagnosis, prevention, and better treatment outcomes.

A pharmaceutical company partnered with Speyside to improve awareness around hemophilia in Mexico, focusing on the challenges of treatment adherence. Speyside assessed the healthcare landscape, mapped stakeholders, and led educational initiatives to build advocacy capacity. The project produced a strategic policy brief, hosted symposiums, and launched an ambassador program. As a result, it identified key barriers, strengthened patient organizations, and laid the groundwork for sustained advocacy and improved health outcomes.

A pharmaceutical company sought to lead efforts in understanding Mexico’s healthcare landscape for Syncytial Respiratory Virus (SRV), especially to improve infant care. Speyside organized a focus group with medical experts and civil society, using stakeholder mapping and support materials to gather insights. The result was a final report with public policy recommendations. These insights helped the company understand challenges in the public healthcare system and provided a clear foundation for future advocacy and engagement with decision-makers.

In 2017, a pharmaceutical company specializing in rare diseases asked Speyside to support and strengthen Patient Advocacy Groups (PAGs) in Brazil, which at the time operated in isolation and lacked coordination. Speyside conducted surveys and interviews to identify weaknesses and training needs, later organizing a webinar on regulatory processes and a hands-on workshop on public policy and advocacy. As a result, PAGs aligned on shared advocacy goals for 2018 and developed a roadmap for joint action—laying the foundation for a stronger, more unified rare disease advocacy network in the country.

Speyside supported a pharmaceutical company in advancing cancer policies in Brazil and facilitating the inclusion of an innovative metastatic melanoma treatment in the public health system (SUS). The work involved regulatory and stakeholder analysis, engagement with decision-makers during CONITEC’s technology incorporation process, and continuous monitoring amid COVID-19 disruptions. These efforts positioned the product as one of the top two treatment options within CONITEC and provided the company with critical insights and ministry connections to support the incorporation process.

Speyside helped a global pharmaceutical company assess medium-sized oncology patient association groups (PAGs) to identify potential long-term partners. The project mapped 90 PAGs, evaluated their institutional capabilities, and conducted targeted interviews with selected groups. Deliverables included a detailed sector study, quantitative and qualitative data reports, and recommendations for engagement, leading to strong relationships with key regional advocates and expanded partnerships across the country.

Speyside worked with a leading rare disease company to design a roadmap for market entry, access, and growth in Hungary and the CEE region. Through stakeholder mapping, policy and regulation analysis, and competitive benchmarking, the project delivered clear, actionable recommendations that transformed the client’s commercial strategy, reduced timelines, and significantly increased the likelihood of achieving public market access.

In 2017, Speyside supported a rare disease pharmaceutical company in introducing an orphan drug for Spinal Muscular Atrophy (SMA) into the Brazilian market. The project strengthened patient associations, built relationships with legislators, and facilitated meetings between advocacy groups, regulators, and the Ministry of Health. These efforts led to ANVISA approving the drug less than a year after FDA registration, sparked a public hearing that advanced reimbursement discussions, and united 10 patient advocacy groups under shared action objectives.